Literature DB >> 18845422

Effects of risperidone on glutamate receptor subtypes in developing rat brain.

Yong Kee Choi1, Matthew P Gardner, Frank I Tarazi.   

Abstract

Levels of ionotropic glutamate (Glu) N-methyl-d-aspartic acid (NMDA), 2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)propionic acid (AMPA), and kainic acid (KA) receptors in forebrain regions of juvenile rats (age 42 days) were quantified after 3 weeks of treatment with three different doses of risperidone (0.3, 1.0 and 3.0 mg/kg) and compared findings to those in adult rats treated with risperidone (3.0 mg/kg/day) previously. Risperidone (at 0.3 mg/kg/day) did not alter levels of three ionotropic Glu receptors in all brain regions examined. Risperidone (at 1.0 and 3.0 mg/kg/day) significantly decreased NMDA binding in caudate-putamen of juvenile and adult animals. In contrast, the same two doses of risperidone decreased NMDA receptors in nucleus accumbens of juveniles and not adults. Risperidone (at 1.0 and 3.0 mg/kg/day) increased AMPA receptors in medial prefrontal cortex and caudate-putamen of juvenile animals, whereas risperidone (at 3.0 mg/kg) increased AMPA receptors in caudate-putamen and hippocampus of adults. Kainate receptors were not altered by any dose of risperidone in any brain region examined in developing and mature animals. The findings indicate that risperidone exerts dose-dependent effects on Glu receptor subtypes in developing animals, and that Glu receptor responses to repeated administration of risperidone are different in juvenile animals than adults.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18845422      PMCID: PMC2659848          DOI: 10.1016/j.euroneuro.2008.08.010

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  51 in total

1.  Localization of ionotropic glutamate receptors in caudate-putamen and nucleus accumbens septi of rat brain: comparison of NMDA, AMPA, and kainate receptors.

Authors:  F I Tarazi; A Campbell; S K Yeghiayan; R J Baldessarini
Journal:  Synapse       Date:  1998-10       Impact factor: 2.562

2.  Antipsychotic drug regulation of AMPA receptor affinity states and GluR1, GluR2 splice variant expression.

Authors:  L McCoy; C Cox; E K Richfield
Journal:  Synapse       Date:  1998-03       Impact factor: 2.562

Review 3.  Glutamate receptors in the mammalian central nervous system.

Authors:  S Ozawa; H Kamiya; K Tsuzuki
Journal:  Prog Neurobiol       Date:  1998-04       Impact factor: 11.685

4.  Risperidone in children and adolescents with pervasive developmental disorder: pilot trial and follow-up.

Authors:  R Perry; C Pataki; D M Munoz-Silva; J Armenteros; R R Silva
Journal:  J Child Adolesc Psychopharmacol       Date:  1997       Impact factor: 2.576

Review 5.  Risperidone in pervasive developmental disorders.

Authors:  Craig A Erickson; Kimberly A Stigler; David J Posey; Christopher J McDougle
Journal:  Expert Rev Neurother       Date:  2005-11       Impact factor: 4.618

6.  Coexpression of striatal dopamine receptor subtypes and excitatory amino acid subunits.

Authors:  M A Ariano; E R Larson; K L Noblett; D R Sibley; M S Levine
Journal:  Synapse       Date:  1997-08       Impact factor: 2.562

7.  Risperidone in the treatment of children and adolescents with schizophrenia: a retrospective study.

Authors:  S J Grcevich; R L Findling; W A Rowane; L Friedman; S C Schulz
Journal:  J Child Adolesc Psychopharmacol       Date:  1996       Impact factor: 2.576

Review 8.  Metabolic side effects of atypical antipsychotics in children: a literature review.

Authors:  Valérie J Fedorowicz; Eric Fombonne
Journal:  J Psychopharmacol       Date:  2005-09       Impact factor: 4.153

9.  Inhibition of the glycine transporter GlyT-1 potentiates the effect of risperidone, but not clozapine, on glutamatergic transmission in the rat medial prefrontal cortex.

Authors:  Asa Konradsson; Monica M Marcus; Peter Hertel; Torgny H Svensson; Kent E Jardemark
Journal:  Synapse       Date:  2006-08       Impact factor: 2.562

Review 10.  Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms.

Authors:  R Lewis
Journal:  Can J Psychiatry       Date:  1998-08       Impact factor: 4.356

View more
  18 in total

1.  Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia.

Authors:  Korrapati V Sathyasaikumar; Erin K Stachowski; Ikwunga Wonodi; Rosalinda C Roberts; Arash Rassoulpour; Robert P McMahon; Robert Schwarcz
Journal:  Schizophr Bull       Date:  2010-10-29       Impact factor: 9.306

2.  Early-life risperidone enhances locomotor responses to amphetamine during adulthood.

Authors:  Bobbie Lee Stubbeman; Clifford J Brown; Justin R Yates; Mark E Bardgett
Journal:  Eur J Pharmacol       Date:  2017-07-14       Impact factor: 4.432

3.  Effects of repeated risperidone exposure on serotonin receptor subtypes in developing rats.

Authors:  Yong Kee Choi; Taylor Moran-Gates; Matthew P Gardner; Frank I Tarazi
Journal:  Eur Neuropsychopharmacol       Date:  2009-10-29       Impact factor: 4.600

4.  Effects of chronic oral treatment with aripiprazole on the expression of NMDA receptor subunits and binding sites in rat brain.

Authors:  Nina Segnitz; Thomas Ferbert; Andrea Schmitt; Peter Gass; Peter J Gebicke-Haerter; Mathias Zink
Journal:  Psychopharmacology (Berl)       Date:  2011-04-12       Impact factor: 4.530

Review 5.  Phelan-McDermid Syndrome and SHANK3: Implications for Treatment.

Authors:  Jesse L Costales; Alexander Kolevzon
Journal:  Neurotherapeutics       Date:  2015-07       Impact factor: 7.620

6.  Selection of Young Animal Models of Autism over Adult: Benefits and Limitations.

Authors:  Raju Paudel; Shamsher Singh
Journal:  Integr Psychol Behav Sci       Date:  2021-01-14

7.  Adult response to olanzapine or clozapine treatment is altered by adolescent antipsychotic exposure: a preclinical test in the phencyclidine hyperlocomotion model.

Authors:  Qing Shu; Gang Hu; Ming Li
Journal:  J Psychopharmacol       Date:  2013-11-20       Impact factor: 4.153

8.  Delayed yet persistent effects of daily risperidone on activity in developing rats.

Authors:  Rachel M Stevens; Matthew A Gannon; Molly S Griffith; Mark E Bardgett
Journal:  Behav Pharmacol       Date:  2016-08       Impact factor: 2.293

9.  Asenapine sensitization from adolescence to adulthood and its potential molecular basis.

Authors:  Qing Shu; Rongyin Qin; Yingzhu Chen; Gang Hu; Ming Li
Journal:  Behav Brain Res       Date:  2014-08-02       Impact factor: 3.332

10.  Long-lasting sensitization induced by repeated risperidone treatment in adolescent Sprague-Dawley rats: a possible D2 receptor mediated phenomenon?

Authors:  Jing Qiao; Jun Gao; Qing Shu; Qinglin Zhang; Gang Hu; Ming Li
Journal:  Psychopharmacology (Berl)       Date:  2013-12-21       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.